ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

ARGX

709.8

+1.66%↑

SHL.DE

34.5

-2.02%↓

PHIA

22.53

-2.38%↓

FRE

36.35

-2.55%↓

SRT3

232.1

-1.23%↓

Home・Stock List・Sanofi SA

Search

Sanofi SA

Open

SectorHealthcare

75.81 -0.95

Overview

Share price change

24h

Current

Min

75.57

Max

77.32

Key metrics
By Trading Economics
Income	-394M 1.6B
Sales	-12B 11B
P/E Sector Avg	19.273 50.102
EPS	1.34
Profit margin	14.354
Employees	74,846
EBITDA	1.5B 2.7B

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+24.76% upside

Dividends
By Dow Jones
Next Earnings	30 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-7.5B 91B
Previous open	76.76
Previous close	75.81

News Sentiment

By Acuity

62%

38%

282 / 344 Healthcare

Sanofi SA Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2026, 09:03 UTC

Earnings

Spain's Santander Profit Climbs Amid Global Portfolio Reshuffle -- Update

29 Apr 2026, 05:27 UTC

Earnings

Santander Books Jump in Profit on Top-Line Growth, Lower Costs

23 Apr 2026, 06:12 UTC

Earnings

Sanofi Posts Higher Sales Amid Leadership Transition

27 May 2026, 20:34 UTC

Acquisitions, Mergers, Takeovers

Webster Financial Stockholders Approve Sale to Banco Santander

7 May 2026, 06:47 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Sanofi Needs Acquisitions to Overcome Pipeline Disappointments -- Market Talk

1 May 2026, 06:14 UTC

Acquisitions, Mergers, Takeovers

Santander UK to Also Pay GBP213M Based on TSB's Tangible NAV

1 May 2026, 06:13 UTC

Acquisitions, Mergers, Takeovers

Santander UK Also Financed Deal From Funding by Parent, Banco Santander

1 May 2026, 06:12 UTC

Acquisitions, Mergers, Takeovers

Santander UK Financed Deal From Existing Cash Resources

1 May 2026, 06:08 UTC

Acquisitions, Mergers, Takeovers

Santander UK Announced Key Terms of Deal July 2025

1 May 2026, 06:03 UTC

Acquisitions, Mergers, Takeovers

Santander UK Buys TSB Banking for GBP2.65B

1 May 2026, 06:02 UTC

Acquisitions, Mergers, Takeovers

Santander UK Buys TSB Banking Group

29 Apr 2026, 12:01 UTC

Earnings

Regeneron Earnings Beat Expectations. Upcoming Cancer Data Matter More for the Stock. -- Barrons.com

29 Apr 2026, 06:27 UTC

Market Talk

Earnings

Santander's Above-Forecast Earnings Should Be Well-Received -- Market Talk

29 Apr 2026, 04:55 UTC

Earnings

Analysts Saw Santander 1Q Loan Loss Provisions EUR3.12B

29 Apr 2026, 04:55 UTC

Earnings

Santander 1Q Loan Loss Provisions EUR3.225B

29 Apr 2026, 04:54 UTC

Earnings

Analysts Saw Santander 1Q Operating Expenses EUR6.57B

29 Apr 2026, 04:54 UTC

Earnings

Santander 1Q Operating Expenses EUR6.48B

29 Apr 2026, 04:52 UTC

Earnings

Santander Backs 2028 View

29 Apr 2026, 04:52 UTC

Earnings

Santander Backs 2026 View

29 Apr 2026, 04:52 UTC

Earnings

Santander 1Q Underlying RoTE 15.2%

29 Apr 2026, 04:51 UTC

Earnings

Santander End-1Q CET1 Ratio 14.4%

29 Apr 2026, 04:51 UTC

Earnings

Analysts Saw Santander 1Q Net Interest Income EUR10.86B

29 Apr 2026, 04:51 UTC

Earnings

Santander 1Q Net Interest Income EUR11.02B

29 Apr 2026, 04:50 UTC

Earnings

Analysts Saw Santander 1Q Underlying Net Pft EUR3.47B

29 Apr 2026, 04:50 UTC

Earnings

Santander 1Q Underlying Pft EUR3.56B

29 Apr 2026, 04:49 UTC

Earnings

Santander 1Q Net Pft EUR5.455B

29 Apr 2026, 04:49 UTC

Earnings

Analysts Saw Santander 1Q Rev EUR15.00B

29 Apr 2026, 04:49 UTC

Earnings

Santander 1Q Rev EUR15.14B

27 Apr 2026, 09:32 UTC

Market Talk

Earnings

Sanofi's Dupixent Sales Growth Set to Moderate -- Market Talk

27 Apr 2026, 09:19 UTC

Market Talk

Sanofi's New CEO Needs to Be Clear on Strategy -- Market Talk

Peer Comparison

Price change

Sanofi SA Forecast

Price Target

By TipRanks

24.76% upside

12 Months Forecast

Average 95.22 EUR 24.76%

High 107 EUR

Low 85 EUR

Based on 9 Wall Street analysts offering 12 month price targets forSanofi SA - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

9 ratings

4

Buy

5

Hold

0

Sell

Based on 9 analysts giving stock ratings to Sanofi SA - Dist in the past 3 months.

Sentiment

By Acuity

282 / 344 Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.

Other stocks from the sector

ARGX

Argenx SE

709.8

SHL.DE

Siemens Healthineers AG

34.5

PHIA

Koninklijke Philips NV

22.53

FRE

Fresenius SE & Co KGaA

36.35

SRT3

Sartorius AG

232.1

Live chat